Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Issue 10 (21st June 2019)

• Record Type: Journal Article
• Authors: Yohe, Marielle E.; Heske, Christine M.; Stewart, Elizabeth; Adamson, Peter C.; Ahmed, Nabil; Antonescu, Cristina R.; Chen, Eleanor; Collins, Natalie; Ehrlich, Alan; Galindo, Rene L.; Gryder, Berkley E.; Hahn, Heidi; Hammond, Sharon; Hatley, Mark E.; Hawkins, Douglas S.; Hayes, Madeline N.; Hayes‐Jordan, Andrea; Helman, Lee J.; Hettmer, Simone; Ignatius, Myron S.; Keller, Charles; Khan, Javed; Kirsch, David G.; Linardic, Corinne M.; Lupo, Philip J.; Rota, Rossella; Shern, Jack F.; Shipley, Janet; Sindiri, Sivasish; Tapscott, Stephen J.; Vakoc, Christopher R.; Wexler, Leonard H.; Langenau, David M.;
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 10(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-06-21
• Subjects: cancer biology -- early‐phase clinical trials -- genomics -- rhabdomyosarcoma; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27869
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.